Methods for modulating immune responses

• US 9,173,908 B2
• Filed: 02/05/2015
• Issued: 11/03/2015
• Est. Priority Date: 01/17/2007
• Status: Active Grant

• Current Assignee: Stemnion, Inc.
• Original Assignee: Stemnion, Inc.
• Inventors: Banas, Richard A., Trumpower, Catherine J., Marshall, Vivienne S.
• Primary Examiner(s): Marvich, Maria
• Application Number:
  US14/614,911
• Publication Number:
  US 20150147358A1
• Time in Patent Office: 271 Days
• US Class Current: 1/1
• CPC Class Codes: A61K 2039/5158 Antigen-pulsed cells, e.g. T-cells
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 35/50 Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61K 38/19 Cytokines; Lymphokines; Interferons
• CPC Class Codes: A61K 38/21 Interferons [IFN]
• CPC Class Codes: A61K 39/001 Preparations to induce tolerance to non-self, e.g. prior to transplantation
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61K 39/461 characterised by the cell type used
• CPC Class Codes: A61K 39/464838 Viral antigens
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/08 Solutions composition of solutions A61K47/00
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: C12N 2502/025 extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton's jelly
• CPC Class Codes: C12N 5/0634 Cells from the blood or the immune system

Abstract

The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents.

Claims

1. A method for down-regulating the immune response an allogeneic graft tissue or organ exhibits when it is transplanted into a subject, the method comprising the step of simultaneously transplanting the allogeneic graft tissue or organ and a purified population of CD 117-negative Amnion-derived Multipotent Progenitor (AMP) cells into the subject such that the AMP cells down-regulate the immune response exhibited by the allogeneic graft tissue or organ.

2. The method of claim 1 wherein the allogeneic graft tissue is bone marrow.

3. The method of claim 1 wherein the immune response exhibited by the allogeneic graft tissue is graft-versus-host disease (GVHD).

4. A method for improving engraftment of an allogeneic graft tissue or organ that is transplanted into a subject in need thereof, the method comprising the step of simultaneously transplanting the allogeneic graft tissue or organ and a purified population of CD117-negative AMP cells into the subject such that the AMP cells down-regulate a GVHD response following the transplantation such that improved engraftment of the allogeneic graft tissue or organ results.

5. The method of claim 4 wherein the transplanted allogeneic graft tissue is bone marrow.